Madrigal Pharmaceuticals, Inc. MDGL Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s total equity?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total equity of $543.45M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s total equity decreased by 23.5% year-over-year, from $710.64M to $543.45M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s total equity has grown at a 20.2% compound annual growth rate (CAGR), from $239.97M to $602.69M.
- What does total equity mean?
- The total value of the company belonging to shareholders after all debts are paid.
- How do you interpret total equity?
- An increase suggests capital accumulation or profitable operations; a decrease may indicate losses or significant share buybacks.
- How does total equity compare across companies?
- Essential for assessing the financial health and leverage of any public company.